-
-
-
-
-
-
-
Verastem Oncology (VSTM) Misses Q3 EPS by 54c
-
-
-
-
-
-
-
Verastem (VSTM) PT Raised to $14 at Guggenheim
-
-
-
-
-
-
-
Verastem (VSTM) PT Lowered to $7 at H.C. Wainwright
-
-
-
-
-
-
-
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022
-
-
-
-
-
-
-
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

